一般演題（口演IS）1 clinical trial

[IS-001] Integration of Veliparib with Front-line Chemotherapy+maintenance in Women with High-grade Serous Carcinoma of Ovarian, Fallopian Tube, or Primary Peritoneal Origin

Robert L. Coleman¹, Gini F. Fleming², Mark F. Brady³, Elizabeth M. Swisher⁴, Karina D. Steffensen⁵, Michael Friedlander⁶, Aikou Okamoto⁷, Kathleen N. Moore⁸, Noa Ben-Baruch⁹, Theresa L. Werner¹⁰, Ana Oaknin¹¹, Joo-Hyun Nam¹², Charles A. Leath III¹³, Shibani Nicum¹⁴, David Cella¹⁵, Danielle M. Sullivan¹⁶, Peter J. Ansell¹⁶, Minh H. Dinh¹⁶, Carol Aghajanian¹⁷, Michael A. Bookman¹⁸ (1.The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2.The University of Chicago Medicine, Chicago, IL, USA, 3.NRG Oncology Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY, USA, 4.University of Washington, Seattle, Washington, USA, 5.Vejle University Hospital of Southern Denmark, Vejle, Denmark, 6.Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, Australia, 7.The Jikei University School of Medicine, Tokyo, Japan, 8.Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 9.Kaplan Medical Center, Rehovot, Israel, 10.Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA, 11.Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology（VHIO）, Barcelona, Spain, 12.University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, 13.University of Alabama at Birmingham, Birmingham, AL, USA, 14.Oxford University Hospitals, Oxford, United Kingdom, 15.Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA, 16.AbbVie Inc., North Chicago, IL, USA, 17.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 18.Kaiser Permanente Northern California, San Francisco, CA, USA)